Sensei Biotherapeutics (NASDAQ:FTH) Earns Buy Rating from Analysts at Guggenheim

Guggenheim assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note released on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $70.00 price target on the stock.

Other analysts also recently issued research reports about the stock. BTIG Research reissued a “buy” rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a report on Friday, August 21st. They issued a “buy” rating and a $56.00 price target for the company. Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective for the company. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Finally, Wall Street Zen raised shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ FTH opened at $34.50 on Wednesday. The firm has a market capitalization of $891.48 million, a P/E ratio of -0.24 and a beta of -0.28. The business has a 50-day simple moving average of $31.96. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, analysts expect that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Insider Buying and Selling

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average price of $23.50 per share, for a total transaction of $117,500.00. Following the acquisition, the chief financial officer owned 46,688 shares in the company, valued at $1,097,168. This represents a 11.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. The trade was a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in Sensei Biotherapeutics in the second quarter valued at $307,000. Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Sensei Biotherapeutics in the 2nd quarter valued at about $3,610,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.